Sinusitis decisions — 2025

The Board remands the claims for service connection for allergic rhinitis, bronchitis, sinusitis, and asthma to provide the Veteran with an examination.

The appeal seeking an initial compensable rating for allergic rhinitis, an initial rating higher than 10 percent for eczema, and service connection for depression was dismissed due to a procedural defect.

The Board granted an initial rating of more than 50 percent for posttraumatic stress disorder and unspecified anxiety disorder, but denied ratings for obstructive sleep apnea, sinusitis, left and right restless leg syndrome, chronic maculopapular dermatosis, alopecia, and service connection claims for various conditions.

The Board denied the veteran's claims for increased ratings and service connection, finding that the evidence did not support a higher rating or service connection for any of the conditions appealed.

The Board denied the Veteran's claim for a higher disability rating for allergic rhinitis, finding that the evidence did not support a rating in excess of 10 percent.

The Board denied a disability rating in excess of 70 percent for generalized anxiety disorder, denied compensable ratings for external hemorrhoids and sinusitis, granted service connection for migraine headaches secondary to sinusitis, and granted service connection for left foot and left shoulder conditions. The claims for increased ratings for urethral stricture, lumbosacral strain, and ulnar neuropathy were remanded.

The Board granted service connection for allergic rhinitis, but denied service connection for left-hand tremors and right-hand tremors. The initial rating for irritable bowel syndrome was also denied.

The Board remands the claims for further development, including obtaining the Veteran's complete service records and scheduling appropriate examinations to clarify the nature and etiology of the claimed disabilities.

The Board remands the claims for further development due to pre-decisional duty to assist errors.

The Veteran's service connection for erectile dysfunction on a direct basis was granted effective September 27, 2019, and special monthly compensation (SMC) based on loss of use of a creative organ was also granted from the same date.

The Board granted a rating of 20 percent for the Veteran's left ankle disability and an initial 30 percent rating for sinusitis.

The Veteran withdrew his appeals for increased ratings and service connection, resulting in the dismissal of all claims.

The Board granted an initial 50 percent rating for tension headaches from February 22, 2019, but denied higher ratings and an initial rating higher than 10 percent for chronic sinusitis.

The Board remands the claims for increased ratings of service-connected conditions to the RO for issuance of a Statement of the Case.

The Board denied an initial compensable evaluation for allergic rhinitis and remanded the issue of service connection for obstructive sleep apnea.

The Board denied service connection for bilateral hearing loss and granted restoration of a 10 percent disability rating for hypertension, while dismissing appeals for compensable ratings for certain surgical scars and maxillary sinusitis. The Board also remanded several issues including service connection for residuals of left varicocelectomy, to include a hydrocele, and other disability ratings.

The Board denied a rating in excess of 30 percent for allergic rhinitis and an initial compensable rating for hypertension, as the evidence did not support higher ratings.

The Board remands the claims for higher disability ratings for hypertension, GERD, allergic rhinitis, and right knee to correct a duty to assist error.

The Board granted service connection for sinusitis and irritable bowel syndrome, as well as increased initial disability ratings of 20 percent and 30 percent, respectively, for cervical spine degenerative arthritis and right shoulder strain.

The Board granted initial disability ratings of 20 percent for left ankle disability, 30 percent for chronic maxillary and frontal sinusitis, and 10 percent for irritable bowel syndrome (IBS).